The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVII.w

Hypogammaglobulinemia - Antibody deficiency

If sustained, may cause infections, and airway disease (bronchiolitis, bronchiectasis). Replacement therapy can be indicated

Publications

Tieu J, Smith RM, Gopaluni S, Kumararatne DS, McClure M, Manson A, Houghton S, Jayne DRW

Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease.

Frontiers in immunology. 2021;12:671503

Farhat L, Dara J, Duberstein S, De A

Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report.

Drug safety - case reports. 2018;5(1):22

Shah S, Jaggi K, Greenberg K, Geetha D

Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis.

Clinical kidney journal. 2017;10(4):470-474

Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, Jayne DR

Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.

Journal of autoimmunity. 2015;57:24-9

Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, Jayne DR

Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.

Journal of autoimmunity. 2015;57:60-5

Levy R, Mahévas M, Galicier L, Boutboul D, Moroch J, Loustau V, Guillaud C, Languille L, Fain O, Bierling P, Khellaf M, Michel M, Oksenhendler E, Godeau B

Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature.

Autoimmunity reviews. 2014;13(10):1055-63

Duraisingham SS, Buckland M, Dempster J, Lorenzo L, Grigoriadou S, Longhurst HJ

Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement.

PloS one. 2014;9(6):e100324

Samson M, Audia S, Lakomy D, Bonnotte B, Tavernier C, Ornetti P

Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology.

Joint bone spine. 2011;78(3):241-5

Cabanillas F, Liboy I, Pavia O, Rivera E

High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication.

Annals of oncology : official journal of the European Society for Medical Oncology. 2006;17(9):1424-7

Verschuuren EA, Stevens SJ, van Imhoff GW, Middeldorp JM, de Boer C, Koëter G, The TH, van Der Bij W

Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication.

Transplantation. 2002;73(1):100-4